Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

Concert Pharmaceuticals logo

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
$8.33
$8.40
52-Week Range
N/A
Volume
N/A
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Remove Ads
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

Feds Just Admitted It—They Can Take Your Cash
The Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money isn't legally yours. Now, think your savings are safe? Think again.
See More Headlines

CNCE Stock Analysis - Frequently Asked Questions

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) posted its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company earned $0.54 million during the quarter, compared to analyst estimates of $0.25 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Concert Pharmaceuticals investors own include Intel (INTC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Global Blood Therapeutics (GBT), Micron Technology (MU), Pfizer (PFE) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/09/2021
Today
4/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Price / Cash Flow
N/A
Book Value
$3.24 per share
Price / Book
N/A

Miscellaneous

Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CNCE) was last updated on 4/5/2025 by MarketBeat.com Staff
From Our Partners